Therapy News and Research

RSS

Mental math exercises linked to better emotional health

Engaging a specific part of the brain during mental math exercises is connected with better emotional health, according to a new brain-scanning study published by Duke researchers in the journal Clinical Psychological Science.

12 Oct 2016

New review questions safety of estrogen replacement therapy

Although individuals often consume natural products because of their potential health benefits, a new review indicates that it is not clear whether the benefits of plant-derived compounds that mimic estrogen outweigh the possible health risks.

11 Oct 2016

Behavioral activation as effective as CBT? An interview with Professor David Richards

BA and CBT are quite fundamentally different. BA is what we call an outside-in treatment, which means it focuses on helping people with depression change the way in which they behave.

10 Oct 2016

Estrogen receptor degrader increases progression-free survival in advanced breast cancer patients

Fulvestrant significantly increases progression-free survival in women with hormone-receptor-positive advanced breast cancer, particularly those with less aggressive lower-volume disease, researchers reported at the ESMO 2016 Congress in Copenhagen

8 Oct 2016

Combination treatment with CDK4/6 inhibitor improves progression-free survival in HR+ breast cancer patients

The addition of the CDK4/6 inhibitor ribociclib to letrozole therapy significantly improves progression-free survival in postmenopausal women with hormone receptor-positive advanced breast cancer, researchers reported today at the ESMO 2016 Congress in Copenhagen.

8 Oct 2016

PARP inhibitor prolongs progression-free survival in patients with recurrent ovarian cancer

The PARP inhibitor niraparib significantly improves the outcome of platinum-sensitive recurrent ovarian cancer, according to full data from the ENGOT-OV16/NOVA trial presented for the first time at the ESMO 2016 Congress in Copenhagen and published in the New England Journal of Medicine.

8 Oct 2016

Immunotherapy redefines treatment approach for metastatic bladder cancer patients

Immunotherapy has shown promising results in first and second line treatment of metastatic bladder cancer in two phase II trials presented at the ESMO 2016 Congress in Copenhagen.

8 Oct 2016

Immune checkpoint inhibitor as adjuvant therapy improves overall survival in patients with stage III melanoma

Ipilimumab as adjuvant therapy significantly improves overall survival in patients with high risk stage III melanoma, according to the EORTC 18071 phase III trial results presented for the first time today at the ESMO 2016 Congress in Copenhagen.

8 Oct 2016

Kessler Foundation receives Spinal Cord Injury Model System Grant from NIDILRR

Kessler Foundation has been awarded a Spinal Cord Injury Model System grant valued at $2,300,000 over 5 years (2016-2021) from the National Institute on Disability, Independent Living, and Rehabilitation Research.

7 Oct 2016

Penn State scientists develop citrate-based fluorescent sensor for diagnosis of cystic fibrosis

Penn State biomaterials scientists have developed a new, inexpensive method for detecting salt concentrations in sweat or other bodily fluids.

7 Oct 2016

Research finds disparity in rates of prostate cancer treatment among African-American, Hispanic men

African-American and Hispanic men in the United States are less likely to receive therapy for prostate cancer compared to Caucasian men — even when they have more aggressive disease, according to new research from Roswell Park Cancer Institute and Vanderbilt University Medical Center.

7 Oct 2016

First comprehensive center opened in Tri-State area to mark new era in care of DMD patients

Nearly 1,000 boys in the New York Tri-State area have been diagnosed with Duchenne Muscular Dystrophy (DMD) and, until now, had to travel out of the state for comprehensive care.

7 Oct 2016

People with PTSD appear to suffer from disrupted context processing, say researchers

For decades, neuroscientists and physicians have tried to get to the bottom of the age-old mystery of post-traumatic stress disorder, to explain why only some people are vulnerable and why they experience so many symptoms and so much disability.

7 Oct 2016

Researchers explain why explain why some tumors recur after immunotherapy

Immunotherapy is a new and highly promising form of treatment for cancer. In many patients, however, tumors recur after immunotherapy.

7 Oct 2016

Added benefit not proven for melanoma drug, IQWiG finds

Talimogene laherparepvec has been approved since December 2015 for adults with advanced melanoma.

7 Oct 2016

No added benefit proven for pulmonary arterial hypertension drug, IQWiG finds

Selexipag is approved for long-term treatment of pulmonary arterial hypertension (PAH) in adults with moderate to severe symptoms.

7 Oct 2016

Survey reveals inequalities in access to new, life saving drugs for melanoma in Europe

Over 5000 patients with metastatic melanoma in Europe are denied access to new, life saving drugs every year, according to a survey presented at the ESMO 2016 Congress in Copenhagen.

7 Oct 2016

New study of Phase II Alzheimer's drug pipeline reveals more ways to combat disease

A new analysis of the Phase II Alzheimer's drug pipeline, conducted by ResearchersAgainstAlzheimer's, revealed 57 new Alzheimer's drugs. According to the analysis, nearly twice as many mechanisms of action are being tested in Phase II than in Phase III clinical trials.

7 Oct 2016

Researchers to explore potential roles of tumor-suppressor gene in kidney cancer

Renal cell carcinoma is the most common type of kidney cancer, and African-Americans and males appear most at risk for this disease that can be asymptomatic until it has spread and become highly lethal, said Dr. Vinata B. Lokeshwar, cancer researcher and chair of the Department of Biochemistry and Molecular Biology at the Medical College of Georgia at Augusta University.

7 Oct 2016

Researchers report high response rate with single drug in phase I/II trial of paediatric brain cancer

A high response rate with a single drug in a phase I/II trial of paediatric brain tumour has set the stage for combination therapy with higher response and lower toxicity, researchers reported at the ESMO 2016 Congress in Copenhagen.

7 Oct 2016

Therapy News and Research

Mental math exercises linked to better emotional health

New review questions safety of estrogen replacement therapy

Behavioral activation as effective as CBT? An interview with Professor David Richards

Estrogen receptor degrader increases progression-free survival in advanced breast cancer patients

Combination treatment with CDK4/6 inhibitor improves progression-free survival in HR+ breast cancer patients

PARP inhibitor prolongs progression-free survival in patients with recurrent ovarian cancer

Immunotherapy redefines treatment approach for metastatic bladder cancer patients

Immune checkpoint inhibitor as adjuvant therapy improves overall survival in patients with stage III melanoma

Kessler Foundation receives Spinal Cord Injury Model System Grant from NIDILRR

Penn State scientists develop citrate-based fluorescent sensor for diagnosis of cystic fibrosis

Research finds disparity in rates of prostate cancer treatment among African-American, Hispanic men

First comprehensive center opened in Tri-State area to mark new era in care of DMD patients

People with PTSD appear to suffer from disrupted context processing, say researchers

Researchers explain why explain why some tumors recur after immunotherapy

Added benefit not proven for melanoma drug, IQWiG finds

No added benefit proven for pulmonary arterial hypertension drug, IQWiG finds

Survey reveals inequalities in access to new, life saving drugs for melanoma in Europe

New study of Phase II Alzheimer's drug pipeline reveals more ways to combat disease

Researchers to explore potential roles of tumor-suppressor gene in kidney cancer

Researchers report high response rate with single drug in phase I/II trial of paediatric brain cancer

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News